Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ: CCCC )

4.340 -0.380 (-8.05%)
Streaming Delayed Price Updated: 1:13 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about C4 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
Clinical Development Initiated in Greater China by Partner Betta Pharmaceuticals 
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
C4T to Host Webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET) 
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Key Takeaways From C4 Therapeutics Analyst Ratings
Via Benzinga
Breaking Down C4 Therapeutics: 4 Analysts Share Their Views
Via Benzinga
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
From C4 Therapeutics, Inc.
Via GlobeNewswire
Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Participate in Upcoming September Investor Conferences
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation
Investor Webcast Moved to Friday, September 13, 2024 
From C4 Therapeutics, Inc.
Via GlobeNewswire
CCCC Stock Earnings: C4 Therapeutics Beats EPS, Beats Revenue for Q2 2024
CCCC stock results show that C4 Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
From C4 Therapeutics, Inc.
Via GlobeNewswire
CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024
CCCC stock results show that C4 Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis 
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.